OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology Communications is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Hsa_circ_0109623 regulates the progression of autoimmune liver disease through Hsa_miR_146b-3p/Sortilin 1–mediated activation of CD4+ T cells	210
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores	155
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	133
Unraveling enhanced liver regeneration in ALPPS: Integrating multi-omics profiling and in vivo CRISPR in mouse models	100
Assessing the risk of surgery in patients with cirrhosis	86
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents	84
GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond	84
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis	76
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	67
Comparison of clinical outcomes in patients with refractory ascites treated with either TIPS, tunneled peritoneal catheter, or ascites pump	64
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	63
	58
Poor emotional well-being and energy are associated with mortality in patients with advanced liver failure	56
Presence of pseudo-Kayser-Fleischer rings in patients without Wilson disease: a prospective cohort study	56
	53
	53
	52
	52
Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care	51
Metabolic Profiling of Bile Acids in the Urine of Patients with Alcohol-Associated Liver Disease	51
In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology	51
Optimal alpha-1 antitrypsin level cutoffs for genotype identification in patients with chronic liver disease	49
Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‐Like Bile Acid Composition	48
Mandatory Hepatology Education for Internal Medicine Residents: Long‐Term Effects and Implications for Workforce Needs	46
Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis	46

Crosstalk of lysyl oxidase-like 1 and lysyl oxidase prolongs their half-lives and regulates liver fibrosis through Notch signal	46
Berberine alleviates concanavalin A–induced autoimmune hepatitis in mice by modulating the gut microbiota	44
Pneumosepsis survival in the setting of obesity leads to persistent steatohepatitis and metabolic dysfunction	42
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	42
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system	41
Lactulose in cirrhosis: Current understanding of efficacy, mechanism, and practical considerations	41
Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA‐2B Score Among US Adults	41
Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR	41
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	39
Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging	38
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD	38
Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver disease	38
Serum amyloid P (PTX2) attenuates hepatic fibrosis in mice by inhibiting the activation of fibrocytes and HSCs	37